CAR T cells

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Amsterdam, the Netherlands – July 14th, 2023 – LUMICKS, a cutting-edge life science tools company and the leading supplier of dynamic single-molecule and cell avidity analysis instruments, today announced the publication of ground-breaking cancer research in Nature. The research, enabled by LUMICKS’ C-Trap® dynamic single-molecule analysis technology, reveals new crucial…

j.yeh19 July 2023

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Press releases

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

Dr. Maher’s powerful research underscores the insights that our revolutionary technology can help researchers around the world discover, and help science better address core challenges in human health, particularly in designing potentially more effective immunotherapies to fight cancer.

j.yeh17 March 2022

Blog posts

New application note shows how to rapidly assess CAR T-cell strategies for multiple myeloma

We are excited to announce that our latest application note, Rapid assessment of CAR T-cell strategies for multiple myeloma with the z-Movi® Cell Avidity Analyzer, is available to download. In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the teams of Dr. Eric Smith (Dana-Farber Cancer Institute) and…

j.yeh16 February 2021

Blog posts

Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi^® results

We are proud to announce the first publication showing results from cell–cell interaction measurements using the z-Movi® Cell Avidity Analyzer! In the study, Fernández de Larrea et al. demonstrate how cell avidity between CAR T cells and target multiple myeloma cell lines correlated with in vivo results. Notably, the cell…

j.yeh29 July 2020

Join our newsletter

First Name

Last Name

Company

Work e-mail *

Country

Get exclusive news on the latest publications, product developments, events and breakthrough science.

Application of interest *

Dynamic single-molecule analysis

Cell avidity analysis

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

If you are human, leave this field blank.

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

New application note shows how to rapidly assess CAR T-cell strategies for multiple myeloma

Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi^® results

Recent Posts

Yearly Archive

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

CAR T cells

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

New application note shows how to rapidly assess CAR T-cell strategies for multiple myeloma

Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi® results

Recent Posts

Yearly Archive

Tags

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi^® results